Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?

Alejandro Marinos, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

Abstract

Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%. Unfortunately, about half of these responding patients will subsequently relapse raising the question of whether allogeneic hemopoietic stem cell transplant should be considered as a consolidative therapy. Currently efforts are focused on defining risk factors for relapse to try and develop algorithms predicting which patients may benefit from allogenic transplant.

Original languageEnglish (US)
Article number101414
JournalBest Practice and Research: Clinical Haematology
Volume35
Issue number4
DOIs
StatePublished - Dec 2022

Keywords

  • Acute lymphoblastic leukemia
  • Allogeneic stem cell transplant
  • Chimeric antigen receptor

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Should all CAR-T therapy for acute lymphoblastic leukemia Be consolidated with allogeneic stem cell transplant?'. Together they form a unique fingerprint.

Cite this